Itching and skin pain in real-life patients with plaque psoriasis: Baseline analysis of the ProLOGUE study

Honma, Masaru; Kanai, Yasumasa; Murotani, Kenta; Nomura, Takanobu; Ito, Kei; Imafuku, Shinichi

doi:10.1016/j.jdermsci.2022.02.005

Cited by 3 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Among the 73 patients enrolled in the study, 66 (90.4%) had itching and 45 (61.6%) had skin pain at baseline. 15 Most (90.4%) patients recorded an Itch NRS score of ≥1 at baseline, and the baseline Itch NRS score distributed almost evenly across 0-10 (Figure S1a). By contrast, more than one-third (38.4%) of the patients recorded a Skin Pain NRS score of 0 (Figure S1b).…”

Section: Patient Baseline Characteristicsmentioning

confidence: 99%

“…The baseline characteristics of patients enrolled in the ProLOGUE study have been previously reported. 13,15 Briefly, 60 patients (82.2%) were men, and the median (quartile [Q] 1-Q3) age was 54.0 (44.0-64.0) years. 13 The median (Q1-Q3) Itch NRS and Skin Pain NRS scores were 4.0 (2.0-7.0) and 1.0 (0.0-3.0), respectively.…”

Section: Patient Baseline Characteristicsmentioning

confidence: 99%

“…To assess the effectiveness of brodalumab in Japanese patients with psoriasis using PROs, a single-arm, open-label, multicenter, prospective study-ProLOGUE-was conducted (Japan Registry of Clinical Trials identifier: jRCTs031180037). [13][14][15] The current analysis of the ProLOGUE study focuses on the change in the levels of itching and skin pain after brodalumab treatment. We also aimed to explore clinically relevant goals for improving itching in psoriasis, in terms of HRQoL and treatment satisfaction.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study

Honma

Kanai

Murotani

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Itching and skin pain are bothersome symptoms of psoriasis, but evidence is limited regarding the treatment effectiveness on these symptoms in daily clinical settings. We assessed the changes in the levels of itching and skin pain after brodalumab treatment in Japanese patients with psoriasis using patient‐reported outcomes (PROs). Patients with psoriasis who have inadequate response to existing treatments were enrolled in the single‐arm, open‐label, multicenter, prospective ProLOGUE study and received brodalumab 210 mg subcutaneously in daily clinical practice. Psoriasis Area and Severity Index (PASI) and PRO assessments were performed at baseline and weeks 12 and 48. Seventy‐three patients (men, 82.2%; median age, 54.0 years) were enrolled. The Itch Numeric Rating Scale (NRS; p < 0.0001 at weeks 12 and 48) and Skin Pain NRS (week 12, p = 0.0004; week 48, p < 0.0001) scores significantly decreased from baseline. The Itch NRS score was significantly higher in patients with a Dermatology Life Quality Index (DLQI) score of ≥2 (vs. 0/1; p < 0.0001 at weeks 12 and 48) and in patients with a Treatment Satisfaction Questionnaire for Medication‐9 (TSQM‐9) global satisfaction domain score of ≤70% (vs. >70%; week 12, p = 0.0120; week 48, p = 0.0348). The Itch NRS score cutoff value for achieving a PASI score of ≤2, DLQI score of 0/1, and TSQM‐9 global satisfaction domain score of >70% was 1 at week 12 and 0 at week 48. Brodalumab treatment was associated with improvement in itching and skin pain in Japanese patients with psoriasis. An Itch NRS score of 0 can be a long‐term treatment goal for psoriasis (Japan Registry of Clinical Trials identifier: jRCTs031180037).

show abstract

Section: Patient Baseline Characteristicsmentioning

confidence: 99%

Section: Patient Baseline Characteristicsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study

Honma

Kanai

Murotani

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular, great overlap in the activity and sensitization of chronic pain and itch is observable. The coexistence of chronic pain and itch is clinically common, such as in psoriasis and atopic dermatitis, two of the most prevalent chronic inflammatory skin diseases, as well as in postherpetic neuralgia [ 1 , 2 , 3 ]. Some investigations on patients with atopic dermatitis have reported that subjects experiencing concomitant pain and itch accounted for about 59–78% of total cases [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…Some investigations on patients with atopic dermatitis have reported that subjects experiencing concomitant pain and itch accounted for about 59–78% of total cases [ 4 , 5 ]. For plaque psoriasis, one study by Honma et al showed that 60.3% of patients reported both pain and itch on the skin [ 1 ]. A study to measure the impact level of pain and itch on the daily tasks of patients with herpes zoster over 50 years old observed that the proportion of patients having both pain and itch was 67% at inclusion time [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

et al. 2022

View full text Add to dashboard Cite

Pain and itch are both important manifestations of various disorders, such as herpes zoster, atopic dermatitis, and psoriasis. Growing evidence suggests that both sensations have shared mediators, overlapping neural circuitry, and similarities in sensitization processes. In fact, pain and itch coexist in some disorders. Determining pharmaceutical agents and targets for treating pain and itch concurrently is of scientific and clinical relevance. Here we review the neurobiology of pain and itch and discuss the pharmaceutical targets as well as novel compounds effective for the concurrent treatment of these sensations.

show abstract

Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report

et al. 2023

View full text Add to dashboard Cite

Therapeutic options for non-small cell lung cancer (NSCLC) have changed with the introduction of immune checkpoint inhibitors. Immunotherapy is generally well tolerated, but can also be associated with severe adverse events, such as the development of new autoimmune diseases. In patients without a history of autoimmune diseases, psoriasis caused by immunotherapy treatment is rarely described in the literature. The present study describes the case of a 68-year-old man with metastatic NSCLC that started chemoimmunotherapy with carboplatin plus pemetrexed plus pembrolizumab. After two cycles of therapy, the patient developed a G3 maculopapular rash. Biopsy confirmed psoriasis and pembrolizumab treatment was discontinued. At the last follow up, the patient was still on maintenance therapy with pemetrexed alone, which is well tolerated. Psoriasis has rarely been reported as an immune-related adverse event. Although the patient had to stop the immunotherapy treatment, the patient is still exhibiting a response to it. Notably, it has previously been described how skin toxicities are associated with a better outcome. Other studies need to be conducted to identify the risk and predictive factors associated with severe immune adverse events and objective response.

show abstract

Itching and skin pain in real-life patients with plaque psoriasis: Baseline analysis of the ProLOGUE study

Cited by 3 publications

References 10 publications

Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study

Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report

Contact Info

Product

Resources

About